Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 11

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 11
---
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the “SEC”). Our SEC reports can be accessed through the “Investors” section of our website. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.

<div align='center'>5</div>

THE OFFERING

| Securities offered by us:    |     | 3,133,333 shares of Common Stock and accompanying Series B-1 Common Warrants to purchase up to 3,133,333 shares of Common Stock and Series B-2 Common Warrants to purchase up to 3,133,333 shares of Common Stock, on a reasonable “best efforts” basis. The shares of Common Stock and accompanying Common Warrants are immediately separable and will be issued separately in this offering, but must initially be purchased together in this offering. The Common Warrants are immediately exercisable, at an exercise price equal to $0.85. The Series B-1 Common Warrants will expire five years from issuance, and the Series B-2 Common Warrants will expire eighteen months from issuance. This prospectus also relates to the offering of the shares of Common Stock issuable upon exercise of the Common Warrants. For more information regarding the Common Warrants, you should carefully read the section titled “Description of Securities to be Registered” in this prospectus. |
| Use of proceeds              |     | We estimate that we will receive approximately $1.9 million in net proceeds from this offering, after deducting the estimated Placement Agents’ fees and estimated offering expenses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 We intend to use the net proceeds from the sale of the securities under this prospectus supplement for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study (expected in the first half of 2026 provided that we are able to obtain sufficient additional funding), for the treatment of existing patients enrolled in the INVINCIBLE-3 Study (including the supply of drug product, maintenance of the study’s database, and the continued safety monitoring and pharmacovigilance in the study), and for working capital and general corporate purposes. In the event the Common Warrants issued in this offering are